SCHEMBL16320252

SCHEMBL16320252

Cc1cc(Nc2cc(F)n[nH]2)nc(Nc2ccc(NC(=O)N(S)c3ccc(Cl)c(C(F)(F)F)c3)nc2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.35
BTK Q06187 2/20 0.35
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TEK Q02763 1/20 0.34
BRAF P15056 2/20 0.34
CDK8 P49336 3/20 0.34
MAPK14 Q16539 1/20 0.34
ABL1 P00519 4/20 0.33
BCR P11274 4/20 0.33
KDR P35968 4/20 0.33
PDGFRB P09619 2/20 0.33
FLT3 P36888 2/20 0.33
CCNC P24863 1/20 0.33
RAF1 P04049 1/20 0.33
KIT P10721 1/20 0.33
PDGFRA P16234 1/20 0.33
FGFR2 P21802 1/20 0.33
GRM4 Q14833 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16320149 0.93 BTK (0.36) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319467 0.92 IGF1R (0.35) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319707 0.91 IGF1R (0.34) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16320438 0.91 IGF1R (0.34) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319940 0.91 ABL1 (0.35) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319838 0.91 KDR (0.39) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319942 0.90 TEK (0.38) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16320464 0.90 ABL1 (0.35) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16319996 0.90 IGF1R (0.34) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1
SCHEMBL16320406 0.90 KDR (0.36) IGF1RBTKAPOBEC3AAPOBEC3GL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221798-B2 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof Zhejian Hisun Pharmaceutical Co., Ltd. (CN) 2015-12-29 US disclosed
US-20140378488-A1 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378488-A1 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF MAP4K2, MAP4K1, MAP4K3 IGF1R 950/4885BTK 448/4885APOBEC3A 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.